Skip to Main Content


General Characteristics

Age:72 years
Disease Origin:Sacral
Disease Status:Recurrent
Source:Silke Bruderlein, Peter Moller
University of Ulm

Molecular Features

Cell morphology:Physaliferous
T expression:Positive; with T amplification
T localization:Nuclear
CD24 expression:Positive
HLA type:A11 View Histocompatibility Report
Chromosomal abnormalities:Multiple, including amplification of T/brachyury and biallelic loss at 9p21 (CDKN2A and CDKN2B loci)
Sequence data:WGS, Exome and Transcriptome data available contact
Validation results:Validation Report

Growth Conditions

Growth medium:IMDM: RPMI-1640 (4:1) +10% FBS
Freeze medium:70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture conditions:Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing instructions:Cell Culture Procedures


Characterized By:
  • Brüderlein S, Sommer J, Meltzer P, Li S, Osada T et al. (2010) Molecular Characterization of Putative Chordoma Cell Lines. Sarcoma: 630129. PubMed: 21253487.

Additional References:

  • Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M et al. Molecular profiling of chordoma. Int J Oncol 44(4):1041-55. PubMed: 24452533.
  • Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH et al. (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14(7):638-47. PubMed: 23792643.